These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38168914)

  • 1. Targeting HDACs for diffuse large B-cell lymphoma therapy.
    Wu C; Song Q; Gao S; Wu S
    Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
    Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
    Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL6 confers resistance to HDAC inhibitors in DLBCL.
    Fan G; Zhang Y; Li Q; Rong R; Chen S; He L; Li B; Zhuang W
    Biochem Pharmacol; 2024 Sep; 227():116466. PubMed ID: 39102989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J
    Leuk Lymphoma; 2024 Jul; 65(7):895-910. PubMed ID: 38497543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
    Luo C; Yu T; Young KH; Yu L
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
    Cao HY; Li L; Xue SL; Dai HP
    Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
    Lee SH; Yoo C; Im S; Jung JH; Choi HJ; Yoo J
    Int J Med Sci; 2014; 11(10):994-1000. PubMed ID: 25076845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
    Liang S; Zhou X; Cai D; Rodrigues-Lima F; Wang L
    Curr Pharm Des; 2021; 27(26):2990-2998. PubMed ID: 34218775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
    Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
    Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
    Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
    Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
    Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.
    Zhang X; Su Q; Zhang Y; Rong R; Chen S; He L; Zhuang W; Li B
    Ann Hematol; 2024 Aug; 103(8):2905-2915. PubMed ID: 38424303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.